OSBoosting Consolidation CostEffective in Stage III NSCLC

OS-Boosting Consolidation Cost-Effective in Stage III NSCLC

12:00 EST 14 Dec 2018 | MedPageToday

(MedPage Today) -- Approach could add up to $768 million in national cancer spending

Original Article: OS-Boosting Consolidation Cost-Effective in Stage III NSCLC

More From BioPortfolio on "OS-Boosting Consolidation Cost-Effective in Stage III NSCLC"